Desarrollo de vacunas de nueva generación contra el virus de influenza

Influenza virus, which causes epidemic infections in man and various species of susceptible\nanimals, continually evolves by exchange of gene segments between different strains, as well as\nincorporation of point mutations. Seasonal influenza vaccines currently in use for prevention are\neffective i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Boado, Lorena Analía
Otros Autores: Álvarez, Paula
Formato: Tesis doctoral acceptedVersion
Lenguaje:Español
Publicado: Facultad de Farmacia y Bioquímica 2014
Materias:
Acceso en línea:http://repositoriouba.sisbi.uba.ar/gsdl/cgi-bin/library.cgi?a=d&c=posgraafa&cl=CL1&d=HWA_786
http://repositoriouba.sisbi.uba.ar/gsdl/collect/posgraafa/index/assoc/HWA_786.dir/786.PDF
Aporte de:
Descripción
Sumario:Influenza virus, which causes epidemic infections in man and various species of susceptible\nanimals, continually evolves by exchange of gene segments between different strains, as well as\nincorporation of point mutations. Seasonal influenza vaccines currently in use for prevention are\neffective in neutralizing infection with homologous strains, but their ability to cover heterologous\nstrains is very low or none. This work is aimed to develop, in the first part, new generation\ninfluenza vaccines through the expression of the immunodominant protein hemagglutinin through\nrecombinant DNA technology in a eukaryotic expression system (baculovirus / insect cells). In the\nsecond part of this work, the generation of a "universal" vaccine with broad spectrum of\nprotection is pursued by means of directing the host immune response to more conserved regions\nof the virus. In this sense, it has been sought to achieve a vaccine based on the internal proteins of\nthe virus, particularly in the Matrix 2 protein and the viral Nucleoprotein. We demonstrate that\nexperimental vaccines based on the ectodomain of the M2 protein can induce humoral or cellular\nimmunity capable of protecting mice from challenge with a lethal dose of influenza virus.